Skip to content
Finance

StanChart Boosts Healthcare Liquidity

By Sarah Chen
1 min read
standard chartered
standard chartered
In this article (4)

Standard Chartered on Monday said it will set aside $1 billion to finance companies that are providing goods and services to tackle the Covid-19 outbreak.

The lender plans to offer financing at preferential rates to firms that are manufacturers and distributors in the pharmaceutical industry, healthcare providers, as well as manufacturers of items such as ventilators, face masks, protective equipment, and sanitizers.

Clearly there’s a cost for companies to switch into these hugely in-demand items, so it’s an area where we can help them get up and running more quickly. At the same time, we want to make sure that existing manufacturers and service providers get the support they need, said Simon Cooper, CEO of StanChart’s corporate and institutional banking division in a media statement.

Financing will come in the form of loans, import finance, export finance, or working capital facilities to help these firms tool up and get their products to market. The bank, which derives about two-thirds of its total operating income from Asia, is also trying to identify companies that may switch into, or add, anti-virus products to their output but have not indicated that they will do so.

Our industry teams are looking across our client base and, given our understanding of clients’ current manufacturing processes, we’re assessing which companies might want to consider adding these items to their production line, Cooper added.

Questions & Answers

Q.

What types of financial support will Standard Chartered offer these companies?

A.

The bank will provide financing through loans, import finance, export finance, or working capital facilities. These are intended to help companies tool up and bring their products to market effectively.

Q.

Which specific companies are eligible for this preferential financing?

A.

Eligible companies include manufacturers and distributors in the pharmaceutical industry, healthcare providers, and those producing items like ventilators, face masks, protective equipment, and sanitizers.

Q.

How will StanChart identify potential new beneficiaries for this funding?

A.

Industry teams are reviewing their client base to identify companies that, based on their current manufacturing processes, might consider adding anti-virus products to their production lines.

Reader pulse

Is StanChart's $1bn healthcare fund a smart play?

19,665 votes so far

Weekly Briefing

Asia's retail intelligence, in your inbox

Monday, Wednesday and a Friday Weekly Wrap: the retail stories, numbers and moves that mattered across Asia. Nothing else, and you can unsubscribe in one click.

  • Top industry moves and market shifts
  • Weekly data-driven analysis from across Asia
  • Monday, Wednesday and the Friday Weekly Wrap

Read by retail operators, investors and brand teams across Asia.

Protected by a quick human check. No spam, ever. Unsubscribe in one click.

SecureGDPR ready